WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Earnings & Revenue

OverviewEarnings
DividendOwnership

AKTX earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$17.7M
Current Profit Margin
0%

AKTX Return on Equity

Current Company
-483.2%
Current Industry
-33%
Current Market
188%
AKTX's Return on Equity (-483.2%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when AKTX announces earnings.

AKTX Return on Assets

Current Company
-139.3%
Current Industry
0.2%
AKTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

AKTX Return on Capital Employed

Current Company
-991.1%
Current Industry
12.2%
AKTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AKTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
AKTX$0.00-$17.74M-$17.75MN/AN/A
ENLV$0.00-$26.10M-$26.93MN/AN/A
EQ$33.76M-$16.94M-$18.17MN/AN/A
LMNL$372.73k$1.03M$1.83M-20.24%-99.22%
EVGN$2.42M-$19.37M-$22.84M+1.68%N/A
View Top Biotech Stocks

AKTX earnings dates

Next earnings date
Sep 27, 2023

Akari Therapeutics Earnings & Revenue FAQ

What were AKTX's earnings last quarter?

On Invalid Date, Akari Therapeutics (NASDAQ: AKTX) reported Q4 2022 earnings per share (EPS) of N/A, up N/A year over year. Total Akari Therapeutics earnings for the quarter were N/A. In the same quarter last year, Akari Therapeutics's earnings per share (EPS) was $0.00.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What was AKTX's earnings growth in the past year?

As of Q3 2023, Akari Therapeutics's earnings has grown year over year. Akari Therapeutics's earnings in the past year totalled -$17.75 million.

What is AKTX's earnings date?

Akari Therapeutics's earnings date is Invalid Date. Add AKTX to your watchlist to be reminded of AKTX's next earnings announcement.

What was AKTX's revenue last quarter?

On Invalid Date, Akari Therapeutics (NASDAQ: AKTX) reported Q4 2022 revenue of N/A up N/A year over year. In the same quarter last year, Akari Therapeutics's revenue was $0.00.

What was AKTX's revenue growth in the past year?

As of Q3 2023, Akari Therapeutics's revenue has grown null year over year. Akari Therapeutics's revenue in the past year totalled $0.00.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.